ストックスクリーナーアプリを入手
35.06
0.93%
-0.33
前日終値:
$35.39
開ける：
$35.11
24時間の取引高:
504.81K
Relative Volume:
0.44
時価総額：
$6.50B
収益：
$520.18M
当期純損益:
$-348.13M
株価収益率:
-18.26
EPS:
-1.92
ネットキャッシュフロー:
$-176.18M
1週間 パフォーマンス:
-5.12%
1か月 パフォーマンス:
-4.52%
6か月 パフォーマンス:
-28.84%
1年 パフォーマンス:
-37.49%
1日の値動き範囲:
$34.59
$35.74
1週間の範囲:
$34.00
$37.37
52週間の値動き範囲:
$30.17
$60.87
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
35.06 | 6.50B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Legend Biotech’s SWOT analysis: carvykti’s strong efficacy drives stock outlook - Investing.com
Piper Sandler maintains Overweight on Legend Biotech, $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Outperform rating on Legend Biotech shares - Investing.com
RBC Capital maintains Outperform rating on Legend Biotech shares By Investing.com - Investing.com South Africa
BMO Capital maintains Legend Biotech at Outperform with $90 target - Investing.com
BMO Capital maintains Legend Biotech at Outperform with $90 target By Investing.com - Investing.com UK
Piper Sandler maintains Overweight on Legend Biotech, $78 target - Investing.com India
Legend Biotech stock price target raised to $75 at H.C. Wainwright - Investing.com India
Legend Biotech reports Q4 earnings beat, revenue tops estimates By Investing.com - Investing.com South Africa
Legend Biotech reports Q4 earnings beat, revenue tops estimates - Investing.com India
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth By Investing.com - Investing.com South Africa
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth - Investing.com India
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics - Yahoo Canada Finance
Legend Biotech CorpADR to Host Earnings Call - ACCESS Newswire
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance
Market Momentum: Aptargroup Inc (ATR) Registers a 0.07 Increase, Closing at 143.28 - The Dwinnex
Legend Biotech Corp ADR (LEGN) rating initates by Redburn Atlantic - Knox Daily
A Guide To The Risks Of Investing In Worksport Ltd (WKSP) - Knox Daily
Legend Biotech Corp ADR (LEGN) stock analysis: A comprehensive overview - US Post News
Beyond Meat Inc (BYND)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Deeper Dive: Understanding Legend Biotech Corp ADR (LEGN) Through its Various Ratios - The Dwinnex
Legend Biotech Corp ADR (LEGN) looking to reclaim success with recent performance - SETE News
CIMG Inc (IMG)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Ratio Analysis: Unpacking XPLR Infrastructure LP (XIFR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ratios in Focus: Analyzing Aurora Mobile Ltd ADR (JG)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyze Legend Biotech Corp ADR (NASDAQ: LEGN) Before Investing. - Stocks Register
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition - Investing.com India
Barclays lifts Johnson & Johnson stock target to $166 - Investing.com
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Legend Biotech stock target cut to $91 by Jefferies - Investing.com South Africa
Legend Biotech keeps stock at Buy rating on strong position - Investing.com India
When will lagging health care stocks return to healthy growth? - The Globe and Mail
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in - FiercePharma
Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India
Overweight rating for Legend Biotech reflects confidence in long-term CARVYKTI revenue - Investing.com India
Legend Biotech stock hits 52-week low at $32.65 amid market challenges - Investing.com
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid challenges - Investing.com India
Legend Biotech stock hits 52-week low at $36.9 amid market shifts By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $36.9 amid market shifts - Investing.com
Analysts Expect ACWI To Hit $136 - Nasdaq
Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):